chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 34.0
Sex: M
Vaccine: SMALL, SMALL
Symptoms: Pyrexia, Rash, Rash erythematous, Rash pustular, Red blood cell sedimentation rate increased
Clinical narrative: This case was received on 02 September 2009 via a QScan search on the VAERS database, under reference number 350022. A 34 year old male patient received a percutaneous injection in the left deltoid of SMALLPOX vaccine, (ACAM2000, lot number VV04003A) on 29 April 2009. The patient received the following vaccines 6 days earlier on 23 April 2009: dose 1 of ANTHRAX, dose 1 on HEP B, INFLUENZA (intramuscular) and TYPHOID. The manufacturer, lot number and site of administration were not reported. The patient was admitted to the hospital on 13 May 2009 with presumptive disseminated vaccinia and right knee cellulitis. Approximately 12 days after receiving SMALLPOX, the patient developed fever, chills, malaise, loss of appetite, headache, sore throat, productive cough and mild shortness of breath. The patient was initially seen on Day 12 (11 May 2009) for upper respiratory illness (URI) - type symptoms. The patient reported a 3 week history of intermittent chest congestion. He was diagnosed with pharyngitis and prescribed Z-pack, ZYRTEC and MUCINEX-D. That night, the patient noted pain and swelling at the SMALLPOX vaccination site and an increase in temperature (not measured). He was seen in the Emergency Room and diagnosed with left arm cellulitis. The patient was prescribed SEPTRA and CLINDAMYCIN. The patient was seen at a medical center for follow-up on 12 May 2009. He had a fever of 101.7 Farenheit. He also had a small tender pustule in right axilla and right knee pain and swelling. By 13 May 2009, the patient developed scattered pustular lesions over the scalp, right hip, and left leg. He also had increased right knee pain and swelling. He was admitted to hospital with a presumptive diagnoses of right knee cellulitis and disseminated vaccinia. An initial assessment by Infectious Disease performed on 14 May 2009 indicated: overall clinical improvement, but continued right knee swelling and warmth without tenderness; blanchable red rash at smallpox vaccine injection site (stable pustule), and over right knee; multiple scattered tense blisters, not excluding palms and soles: vesicles in various stages, characterized as yellow on erythematous base, umbilicated or ruptured, some becoming pustular, some with honey-colored crusts; distributed over scalp, neck, shoulders axillae, upper extremities, trunk, buttocks, lower extremities. Laboratory tests performed between 13 May 2009 and 15 May 2009 include: ESR 66-75 (high); CRP 10-12 (high); WBC 3000 range (low); Hematocrit 31-32 (low); Platelet 65-74 (low); normal chemistries, liver panel, LDH, ferritin, retic count, coagulation tests, and urinalysis; negative wound, blood and urine cultures. The patient recovered. There may be a discrepancy between the event date field and the onset date information in the free text narrative field in the data reported. Latency has been calculated using the event date. List of documents held by sender: none.
Age: 34.0
Sex: M
Vaccine: SMALL, SMALL
Symptoms: Respiratory tract congestion, Reticulocyte count normal, Scab, Serum ferritin normal, Skin lesion
Clinical narrative: This case was received on 02 September 2009 via a QScan search on the VAERS database, under reference number 350022. A 34 year old male patient received a percutaneous injection in the left deltoid of SMALLPOX vaccine, (ACAM2000, lot number VV04003A) on 29 April 2009. The patient received the following vaccines 6 days earlier on 23 April 2009: dose 1 of ANTHRAX, dose 1 on HEP B, INFLUENZA (intramuscular) and TYPHOID. The manufacturer, lot number and site of administration were not reported. The patient was admitted to the hospital on 13 May 2009 with presumptive disseminated vaccinia and right knee cellulitis. Approximately 12 days after receiving SMALLPOX, the patient developed fever, chills, malaise, loss of appetite, headache, sore throat, productive cough and mild shortness of breath. The patient was initially seen on Day 12 (11 May 2009) for upper respiratory illness (URI) - type symptoms. The patient reported a 3 week history of intermittent chest congestion. He was diagnosed with pharyngitis and prescribed Z-pack, ZYRTEC and MUCINEX-D. That night, the patient noted pain and swelling at the SMALLPOX vaccination site and an increase in temperature (not measured). He was seen in the Emergency Room and diagnosed with left arm cellulitis. The patient was prescribed SEPTRA and CLINDAMYCIN. The patient was seen at a medical center for follow-up on 12 May 2009. He had a fever of 101.7 Farenheit. He also had a small tender pustule in right axilla and right knee pain and swelling. By 13 May 2009, the patient developed scattered pustular lesions over the scalp, right hip, and left leg. He also had increased right knee pain and swelling. He was admitted to hospital with a presumptive diagnoses of right knee cellulitis and disseminated vaccinia. An initial assessment by Infectious Disease performed on 14 May 2009 indicated: overall clinical improvement, but continued right knee swelling and warmth without tenderness; blanchable red rash at smallpox vaccine injection site (stable pustule), and over right knee; multiple scattered tense blisters, not excluding palms and soles: vesicles in various stages, characterized as yellow on erythematous base, umbilicated or ruptured, some becoming pustular, some with honey-colored crusts; distributed over scalp, neck, shoulders axillae, upper extremities, trunk, buttocks, lower extremities. Laboratory tests performed between 13 May 2009 and 15 May 2009 include: ESR 66-75 (high); CRP 10-12 (high); WBC 3000 range (low); Hematocrit 31-32 (low); Platelet 65-74 (low); normal chemistries, liver panel, LDH, ferritin, retic count, coagulation tests, and urinalysis; negative wound, blood and urine cultures. The patient recovered. There may be a discrepancy between the event date field and the onset date information in the free text narrative field in the data reported. Latency has been calculated using the event date. List of documents held by sender: none.
Age: 34.0
Sex: M
Vaccine: SMALL, SMALL
Symptoms: Skin oedema, Skin warm, Upper respiratory tract infection, Urine analysis normal, Vaccination site pain
Clinical narrative: This case was received on 02 September 2009 via a QScan search on the VAERS database, under reference number 350022. A 34 year old male patient received a percutaneous injection in the left deltoid of SMALLPOX vaccine, (ACAM2000, lot number VV04003A) on 29 April 2009. The patient received the following vaccines 6 days earlier on 23 April 2009: dose 1 of ANTHRAX, dose 1 on HEP B, INFLUENZA (intramuscular) and TYPHOID. The manufacturer, lot number and site of administration were not reported. The patient was admitted to the hospital on 13 May 2009 with presumptive disseminated vaccinia and right knee cellulitis. Approximately 12 days after receiving SMALLPOX, the patient developed fever, chills, malaise, loss of appetite, headache, sore throat, productive cough and mild shortness of breath. The patient was initially seen on Day 12 (11 May 2009) for upper respiratory illness (URI) - type symptoms. The patient reported a 3 week history of intermittent chest congestion. He was diagnosed with pharyngitis and prescribed Z-pack, ZYRTEC and MUCINEX-D. That night, the patient noted pain and swelling at the SMALLPOX vaccination site and an increase in temperature (not measured). He was seen in the Emergency Room and diagnosed with left arm cellulitis. The patient was prescribed SEPTRA and CLINDAMYCIN. The patient was seen at a medical center for follow-up on 12 May 2009. He had a fever of 101.7 Farenheit. He also had a small tender pustule in right axilla and right knee pain and swelling. By 13 May 2009, the patient developed scattered pustular lesions over the scalp, right hip, and left leg. He also had increased right knee pain and swelling. He was admitted to hospital with a presumptive diagnoses of right knee cellulitis and disseminated vaccinia. An initial assessment by Infectious Disease performed on 14 May 2009 indicated: overall clinical improvement, but continued right knee swelling and warmth without tenderness; blanchable red rash at smallpox vaccine injection site (stable pustule), and over right knee; multiple scattered tense blisters, not excluding palms and soles: vesicles in various stages, characterized as yellow on erythematous base, umbilicated or ruptured, some becoming pustular, some with honey-colored crusts; distributed over scalp, neck, shoulders axillae, upper extremities, trunk, buttocks, lower extremities. Laboratory tests performed between 13 May 2009 and 15 May 2009 include: ESR 66-75 (high); CRP 10-12 (high); WBC 3000 range (low); Hematocrit 31-32 (low); Platelet 65-74 (low); normal chemistries, liver panel, LDH, ferritin, retic count, coagulation tests, and urinalysis; negative wound, blood and urine cultures. The patient recovered. There may be a discrepancy between the event date field and the onset date information in the free text narrative field in the data reported. Latency has been calculated using the event date. List of documents held by sender: none.
Age: 34.0
Sex: M
Vaccine: SMALL, SMALL
Symptoms: Vaccination site swelling, Viral test negative, White blood cell count decreased
Clinical narrative: This case was received on 02 September 2009 via a QScan search on the VAERS database, under reference number 350022. A 34 year old male patient received a percutaneous injection in the left deltoid of SMALLPOX vaccine, (ACAM2000, lot number VV04003A) on 29 April 2009. The patient received the following vaccines 6 days earlier on 23 April 2009: dose 1 of ANTHRAX, dose 1 on HEP B, INFLUENZA (intramuscular) and TYPHOID. The manufacturer, lot number and site of administration were not reported. The patient was admitted to the hospital on 13 May 2009 with presumptive disseminated vaccinia and right knee cellulitis. Approximately 12 days after receiving SMALLPOX, the patient developed fever, chills, malaise, loss of appetite, headache, sore throat, productive cough and mild shortness of breath. The patient was initially seen on Day 12 (11 May 2009) for upper respiratory illness (URI) - type symptoms. The patient reported a 3 week history of intermittent chest congestion. He was diagnosed with pharyngitis and prescribed Z-pack, ZYRTEC and MUCINEX-D. That night, the patient noted pain and swelling at the SMALLPOX vaccination site and an increase in temperature (not measured). He was seen in the Emergency Room and diagnosed with left arm cellulitis. The patient was prescribed SEPTRA and CLINDAMYCIN. The patient was seen at a medical center for follow-up on 12 May 2009. He had a fever of 101.7 Farenheit. He also had a small tender pustule in right axilla and right knee pain and swelling. By 13 May 2009, the patient developed scattered pustular lesions over the scalp, right hip, and left leg. He also had increased right knee pain and swelling. He was admitted to hospital with a presumptive diagnoses of right knee cellulitis and disseminated vaccinia. An initial assessment by Infectious Disease performed on 14 May 2009 indicated: overall clinical improvement, but continued right knee swelling and warmth without tenderness; blanchable red rash at smallpox vaccine injection site (stable pustule), and over right knee; multiple scattered tense blisters, not excluding palms and soles: vesicles in various stages, characterized as yellow on erythematous base, umbilicated or ruptured, some becoming pustular, some with honey-colored crusts; distributed over scalp, neck, shoulders axillae, upper extremities, trunk, buttocks, lower extremities. Laboratory tests performed between 13 May 2009 and 15 May 2009 include: ESR 66-75 (high); CRP 10-12 (high); WBC 3000 range (low); Hematocrit 31-32 (low); Platelet 65-74 (low); normal chemistries, liver panel, LDH, ferritin, retic count, coagulation tests, and urinalysis; negative wound, blood and urine cultures. The patient recovered. There may be a discrepancy between the event date field and the onset date information in the free text narrative field in the data reported. Latency has been calculated using the event date. List of documents held by sender: none.
Age: 28.0
Sex: F
Vaccine: ANTH, SMALL
Symptoms: Herpes simplex serology negative, Lymphadenopathy, Pruritus, Rash erythematous, Rash maculo-papular
Clinical narrative: This case was received on 02 September 2009 via a QScan search on the VAERS database, under reference number 350026. A 28 year old female patient received the following vaccines on 07 June 2009: a percutaneous injection in the right deltoid of ACAM2000 (lot number VV04003A) and a second dose of anthrax vaccine (Michigan Department of Public Health, lot number FAV193). The patient received an initial dose of ACAM2000 (lot number not reported) on 2 May 2009 which resulted in an equivocal take. Nine days after the second dose of smallpox vaccine, live and anthrax vaccine, the patient developed an itchy, red rash over both hands. The rash spread up the right forearm the following day. The patient denied fever, chills, or other systemic symptoms. She was well prior to vaccination and on the day of vaccinations. She denied sick contacts and other environmental exposures. On Day 10, the patient's rash was reported as non-urticarial, patchy, and maculopapular. The rash was on the bilateral dorsal surfaces of the hands with faint erythema on the palms. There were no vesicles. The smallpox vaccination right on the right deltoid was consistent with a major take. There was no surrounding erythema, edema, or satellite lesions. There was mild right axillary lymphadenopathy. The patient was treated with antihistamine. Dramatic improvement was noted 24 hours later. On Day 11, the patient reported similar but milder eruptions over bilateral dorsal feet and lateral ankles which completely resolved by Day 12. Mild hyperpigmentation over the dorsal hands only was reported on Day 12. The palms were clear and there were no new eruptions. By Day 16, there was no recurrence. The patient has no prior history of eczema, atopic dermatitis, immunosuppression, or herpes simplex virus. She has no known allergies to drugs, foods, latex, or insect stings. She had natural varicella zoster virus infection in childhood. On 17 June 2009, herpes simplex virus 1 and 2, IgM and IgG were negative. Testing for VSV antibody was reported as immune. NOTE: Although the manufacturer was reported as unknown in this case, ACAM2000 was the only licensed smallpox vaccine at the time of the patient's vaccination.
Age: 28.0
Sex: F
Vaccine: ANTH, SMALL
Symptoms: Skin hyperpigmentation, Varicella zoster serology negative
Clinical narrative: This case was received on 02 September 2009 via a QScan search on the VAERS database, under reference number 350026. A 28 year old female patient received the following vaccines on 07 June 2009: a percutaneous injection in the right deltoid of ACAM2000 (lot number VV04003A) and a second dose of anthrax vaccine (Michigan Department of Public Health, lot number FAV193). The patient received an initial dose of ACAM2000 (lot number not reported) on 2 May 2009 which resulted in an equivocal take. Nine days after the second dose of smallpox vaccine, live and anthrax vaccine, the patient developed an itchy, red rash over both hands. The rash spread up the right forearm the following day. The patient denied fever, chills, or other systemic symptoms. She was well prior to vaccination and on the day of vaccinations. She denied sick contacts and other environmental exposures. On Day 10, the patient's rash was reported as non-urticarial, patchy, and maculopapular. The rash was on the bilateral dorsal surfaces of the hands with faint erythema on the palms. There were no vesicles. The smallpox vaccination right on the right deltoid was consistent with a major take. There was no surrounding erythema, edema, or satellite lesions. There was mild right axillary lymphadenopathy. The patient was treated with antihistamine. Dramatic improvement was noted 24 hours later. On Day 11, the patient reported similar but milder eruptions over bilateral dorsal feet and lateral ankles which completely resolved by Day 12. Mild hyperpigmentation over the dorsal hands only was reported on Day 12. The palms were clear and there were no new eruptions. By Day 16, there was no recurrence. The patient has no prior history of eczema, atopic dermatitis, immunosuppression, or herpes simplex virus. She has no known allergies to drugs, foods, latex, or insect stings. She had natural varicella zoster virus infection in childhood. On 17 June 2009, herpes simplex virus 1 and 2, IgM and IgG were negative. Testing for VSV antibody was reported as immune. NOTE: Although the manufacturer was reported as unknown in this case, ACAM2000 was the only licensed smallpox vaccine at the time of the patient's vaccination.
Age: 25.0
Sex: M
Vaccine: SMALL
Symptoms: Back pain, Blood creatine phosphokinase MB normal, Blood creatine phosphokinase increased, Chest discomfort, Chest pain
Clinical narrative: This case was received on 02 September 2009 via a QScan search on the VAERS database, under reference number 350422. A 25 year old patient received a percutaneous injection of ACAM2000 (lot number not reported) on 14 May 2008. Six days after vaccination, the patient developed myopericarditis. The patient initially reported a 12 hour history of sharp, constant left sided chest pain, mild upper back pain, trapezius pain, occipital headache, shortness of breath and a non productive, dry cough. The back pain and chest pain occurred when the patient was at rest. It was worse in the supine position and with inspiration. He was diagnosed and treated by providers. The treatment was not specified. The report does not indicate that the patient was hospitalized however the patient was reported to be medevaced in early June 2008. The patient returned to duty in late June or early July 2008. On 20 May 2008, the patient had the following laboratory findings: WBC, 15; CK, 1358; CKMB, negative; and troponin, negative. On 21 May 2008, the patient's CK level was 917 and a troponin was reported as positive. On 24 May 2008, the patient had a WBC, 3.2; CK, 150; troponin, neg (<0.5); and negative myoglobulin. On 25 May 2008, the patient's CK level was 104 and a CBC, troponin and CKMB were reported as negative/normal. The patient had an electrocardiogram that showed normal sinus rhythm with a heart rate of 79 beats per minute and ST elevation V2-6. The patient also had an echocardiogram in May 2008 which was normal. On 21 July 2008, the patient was seen for an 8 week evaluation. The patient had sporadic episodes of chest pain and pressure that continued following his return to duty. He reported that the discomfort was improving and he denied any other symptoms. His stress test was normal. He was treated with COLCHICINE (one tablet per day for 2 months). On 21 September 2008, the patient had no new symptoms, chest pain or palpitations. On 19 December 2008, the patient was evaluated by internal medicine and cardiology for palpitations. An electrocardiogram on 19 December 2008 was normal. The patient had a stress test on 12 January 2009 which was normal. The patient recovered. Note: Two different dates of administration were provided in the report. The date of administration was reported as 13 May 2008 in the structured vaccination date field and as 14 May 2008 in the same narrative. Latency has been calculated using the date in the case narrative. List of documents held by sender: none.
Age: 25.0
Sex: M
Vaccine: SMALL
Symptoms: Cough, Discomfort, Dyspnoea, Echocardiogram normal, Electrocardiogram normal
Clinical narrative: This case was received on 02 September 2009 via a QScan search on the VAERS database, under reference number 350422. A 25 year old patient received a percutaneous injection of ACAM2000 (lot number not reported) on 14 May 2008. Six days after vaccination, the patient developed myopericarditis. The patient initially reported a 12 hour history of sharp, constant left sided chest pain, mild upper back pain, trapezius pain, occipital headache, shortness of breath and a non productive, dry cough. The back pain and chest pain occurred when the patient was at rest. It was worse in the supine position and with inspiration. He was diagnosed and treated by providers. The treatment was not specified. The report does not indicate that the patient was hospitalized however the patient was reported to be medevaced in early June 2008. The patient returned to duty in late June or early July 2008. On 20 May 2008, the patient had the following laboratory findings: WBC, 15; CK, 1358; CKMB, negative; and troponin, negative. On 21 May 2008, the patient's CK level was 917 and a troponin was reported as positive. On 24 May 2008, the patient had a WBC, 3.2; CK, 150; troponin, neg (<0.5); and negative myoglobulin. On 25 May 2008, the patient's CK level was 104 and a CBC, troponin and CKMB were reported as negative/normal. The patient had an electrocardiogram that showed normal sinus rhythm with a heart rate of 79 beats per minute and ST elevation V2-6. The patient also had an echocardiogram in May 2008 which was normal. On 21 July 2008, the patient was seen for an 8 week evaluation. The patient had sporadic episodes of chest pain and pressure that continued following his return to duty. He reported that the discomfort was improving and he denied any other symptoms. His stress test was normal. He was treated with COLCHICINE (one tablet per day for 2 months). On 21 September 2008, the patient had no new symptoms, chest pain or palpitations. On 19 December 2008, the patient was evaluated by internal medicine and cardiology for palpitations. An electrocardiogram on 19 December 2008 was normal. The patient had a stress test on 12 January 2009 which was normal. The patient recovered. Note: Two different dates of administration were provided in the report. The date of administration was reported as 13 May 2008 in the structured vaccination date field and as 14 May 2008 in the same narrative. Latency has been calculated using the date in the case narrative. List of documents held by sender: none.
Age: 25.0
Sex: M
Vaccine: SMALL
Symptoms: Headache, Myalgia, Myoglobin blood, Myopericarditis, Palpitations
Clinical narrative: This case was received on 02 September 2009 via a QScan search on the VAERS database, under reference number 350422. A 25 year old patient received a percutaneous injection of ACAM2000 (lot number not reported) on 14 May 2008. Six days after vaccination, the patient developed myopericarditis. The patient initially reported a 12 hour history of sharp, constant left sided chest pain, mild upper back pain, trapezius pain, occipital headache, shortness of breath and a non productive, dry cough. The back pain and chest pain occurred when the patient was at rest. It was worse in the supine position and with inspiration. He was diagnosed and treated by providers. The treatment was not specified. The report does not indicate that the patient was hospitalized however the patient was reported to be medevaced in early June 2008. The patient returned to duty in late June or early July 2008. On 20 May 2008, the patient had the following laboratory findings: WBC, 15; CK, 1358; CKMB, negative; and troponin, negative. On 21 May 2008, the patient's CK level was 917 and a troponin was reported as positive. On 24 May 2008, the patient had a WBC, 3.2; CK, 150; troponin, neg (<0.5); and negative myoglobulin. On 25 May 2008, the patient's CK level was 104 and a CBC, troponin and CKMB were reported as negative/normal. The patient had an electrocardiogram that showed normal sinus rhythm with a heart rate of 79 beats per minute and ST elevation V2-6. The patient also had an echocardiogram in May 2008 which was normal. On 21 July 2008, the patient was seen for an 8 week evaluation. The patient had sporadic episodes of chest pain and pressure that continued following his return to duty. He reported that the discomfort was improving and he denied any other symptoms. His stress test was normal. He was treated with COLCHICINE (one tablet per day for 2 months). On 21 September 2008, the patient had no new symptoms, chest pain or palpitations. On 19 December 2008, the patient was evaluated by internal medicine and cardiology for palpitations. An electrocardiogram on 19 December 2008 was normal. The patient had a stress test on 12 January 2009 which was normal. The patient recovered. Note: Two different dates of administration were provided in the report. The date of administration was reported as 13 May 2008 in the structured vaccination date field and as 14 May 2008 in the same narrative. Latency has been calculated using the date in the case narrative. List of documents held by sender: none.
Age: 25.0
Sex: M
Vaccine: SMALL
Symptoms: Stress echocardiogram, Troponin, White blood cell count increased
Clinical narrative: This case was received on 02 September 2009 via a QScan search on the VAERS database, under reference number 350422. A 25 year old patient received a percutaneous injection of ACAM2000 (lot number not reported) on 14 May 2008. Six days after vaccination, the patient developed myopericarditis. The patient initially reported a 12 hour history of sharp, constant left sided chest pain, mild upper back pain, trapezius pain, occipital headache, shortness of breath and a non productive, dry cough. The back pain and chest pain occurred when the patient was at rest. It was worse in the supine position and with inspiration. He was diagnosed and treated by providers. The treatment was not specified. The report does not indicate that the patient was hospitalized however the patient was reported to be medevaced in early June 2008. The patient returned to duty in late June or early July 2008. On 20 May 2008, the patient had the following laboratory findings: WBC, 15; CK, 1358; CKMB, negative; and troponin, negative. On 21 May 2008, the patient's CK level was 917 and a troponin was reported as positive. On 24 May 2008, the patient had a WBC, 3.2; CK, 150; troponin, neg (<0.5); and negative myoglobulin. On 25 May 2008, the patient's CK level was 104 and a CBC, troponin and CKMB were reported as negative/normal. The patient had an electrocardiogram that showed normal sinus rhythm with a heart rate of 79 beats per minute and ST elevation V2-6. The patient also had an echocardiogram in May 2008 which was normal. On 21 July 2008, the patient was seen for an 8 week evaluation. The patient had sporadic episodes of chest pain and pressure that continued following his return to duty. He reported that the discomfort was improving and he denied any other symptoms. His stress test was normal. He was treated with COLCHICINE (one tablet per day for 2 months). On 21 September 2008, the patient had no new symptoms, chest pain or palpitations. On 19 December 2008, the patient was evaluated by internal medicine and cardiology for palpitations. An electrocardiogram on 19 December 2008 was normal. The patient had a stress test on 12 January 2009 which was normal. The patient recovered. Note: Two different dates of administration were provided in the report. The date of administration was reported as 13 May 2008 in the structured vaccination date field and as 14 May 2008 in the same narrative. Latency has been calculated using the date in the case narrative. List of documents held by sender: none.
Age: 38.0
Sex: M
Vaccine: ANTH, SMALL
Symptoms: Eye pruritus, Headache, Ocular hyperaemia, Optic neuropathy, Pain
Clinical narrative: This case was received on 14 September 2009 via a QScan search on the VAERS database, under reference number 350643. A 38 year-old male patient received the following vaccines on 03 April 2009: a percutaneous injection of SMALLPOX vaccine (ACAM2000, lot number not reported); and ANTHRAX vaccine (lot number FAV164). The patient reportedly received two doses of ANTHRAX vaccine. It is not clear from the report if the dose given on 03 April 2009 is Dose 1 or Dose 2. The patient was diagnosed with optic neuropathy with pupillary defect by an ophthalmologist. The patient reported visual changes after receiving Dose 1 and Dose 2 of ANTHRAX vaccine. At the time of vaccination with Dose 1 of ANTHRAX vaccine, the patient reported black vision which lasted 3 to 6 seconds. One hour later, the patient complained of difficulty reading. He had difficulty focusing on letters and numbers and was unable to see clearly. He had to squint and concentrate hard to interpret. The patient also complained of photophobia. He denied any blurring or difficulty seeing colors or objects. The patient's eyes appeared red and itched. The patient did not have a headache, dizziness, upper respiratory illness or other signs and symptoms. The patient's vision remained out of focus for 3 weeks, at which point he "seemed used to it". After receiving Dose 2 of ANTHRAX vaccine, the patient had the same signs and symptoms. In addition, the patient complained of a frontal headache lasting 3 days and with pain reported as 8/10 on a pain scale. The headache resolved. His light sensitivity was reportedly worse, requiring sun glasses when outside and fluorescent lights bothered him. The patient has a history of eye allergies. PATENOL was used for itchy eyes mainly in June and July due to cactus and other desert flowers blooming. A report from an optometrist advised the patient had slight myopia correctable to 20/20 (lasik surgery had vision at 20/10) with no corneal lesions or anterior chamber changes and no inflammation. Although the manufacturer was reported as unknown in this case, ACAM2000 was the only licensed smallpox vaccine at the time of the patient's vaccination. List of documents held by sender: none.
Age: 38.0
Sex: M
Vaccine: ANTH, SMALL
Symptoms: Photophobia, Pupillary disorder, Strabismus, Vision blurred, Visual acuity reduced
Clinical narrative: This case was received on 14 September 2009 via a QScan search on the VAERS database, under reference number 350643. A 38 year-old male patient received the following vaccines on 03 April 2009: a percutaneous injection of SMALLPOX vaccine (ACAM2000, lot number not reported); and ANTHRAX vaccine (lot number FAV164). The patient reportedly received two doses of ANTHRAX vaccine. It is not clear from the report if the dose given on 03 April 2009 is Dose 1 or Dose 2. The patient was diagnosed with optic neuropathy with pupillary defect by an ophthalmologist. The patient reported visual changes after receiving Dose 1 and Dose 2 of ANTHRAX vaccine. At the time of vaccination with Dose 1 of ANTHRAX vaccine, the patient reported black vision which lasted 3 to 6 seconds. One hour later, the patient complained of difficulty reading. He had difficulty focusing on letters and numbers and was unable to see clearly. He had to squint and concentrate hard to interpret. The patient also complained of photophobia. He denied any blurring or difficulty seeing colors or objects. The patient's eyes appeared red and itched. The patient did not have a headache, dizziness, upper respiratory illness or other signs and symptoms. The patient's vision remained out of focus for 3 weeks, at which point he "seemed used to it". After receiving Dose 2 of ANTHRAX vaccine, the patient had the same signs and symptoms. In addition, the patient complained of a frontal headache lasting 3 days and with pain reported as 8/10 on a pain scale. The headache resolved. His light sensitivity was reportedly worse, requiring sun glasses when outside and fluorescent lights bothered him. The patient has a history of eye allergies. PATENOL was used for itchy eyes mainly in June and July due to cactus and other desert flowers blooming. A report from an optometrist advised the patient had slight myopia correctable to 20/20 (lasik surgery had vision at 20/10) with no corneal lesions or anterior chamber changes and no inflammation. Although the manufacturer was reported as unknown in this case, ACAM2000 was the only licensed smallpox vaccine at the time of the patient's vaccination. List of documents held by sender: none.
Age: 38.0
Sex: M
Vaccine: ANTH, SMALL
Symptoms: Visual impairment
Clinical narrative: This case was received on 14 September 2009 via a QScan search on the VAERS database, under reference number 350643. A 38 year-old male patient received the following vaccines on 03 April 2009: a percutaneous injection of SMALLPOX vaccine (ACAM2000, lot number not reported); and ANTHRAX vaccine (lot number FAV164). The patient reportedly received two doses of ANTHRAX vaccine. It is not clear from the report if the dose given on 03 April 2009 is Dose 1 or Dose 2. The patient was diagnosed with optic neuropathy with pupillary defect by an ophthalmologist. The patient reported visual changes after receiving Dose 1 and Dose 2 of ANTHRAX vaccine. At the time of vaccination with Dose 1 of ANTHRAX vaccine, the patient reported black vision which lasted 3 to 6 seconds. One hour later, the patient complained of difficulty reading. He had difficulty focusing on letters and numbers and was unable to see clearly. He had to squint and concentrate hard to interpret. The patient also complained of photophobia. He denied any blurring or difficulty seeing colors or objects. The patient's eyes appeared red and itched. The patient did not have a headache, dizziness, upper respiratory illness or other signs and symptoms. The patient's vision remained out of focus for 3 weeks, at which point he "seemed used to it". After receiving Dose 2 of ANTHRAX vaccine, the patient had the same signs and symptoms. In addition, the patient complained of a frontal headache lasting 3 days and with pain reported as 8/10 on a pain scale. The headache resolved. His light sensitivity was reportedly worse, requiring sun glasses when outside and fluorescent lights bothered him. The patient has a history of eye allergies. PATENOL was used for itchy eyes mainly in June and July due to cactus and other desert flowers blooming. A report from an optometrist advised the patient had slight myopia correctable to 20/20 (lasik surgery had vision at 20/10) with no corneal lesions or anterior chamber changes and no inflammation. Although the manufacturer was reported as unknown in this case, ACAM2000 was the only licensed smallpox vaccine at the time of the patient's vaccination. List of documents held by sender: none.
Age: 37.0
Sex: M
Vaccine: SMALL
Symptoms: Dysphagia, Injection site pustule, Lymph node pain, Oropharyngeal pain, Pyrexia
Clinical narrative: This case was received on 14 September 2009 via a QScan search on the VAERS database, under reference number 351130. A 37 year old male patient received a percutaneous injection of smallpox (vaccinia) vaccine (ACAM2000, lot number VV04-003A) on 01 July 2009. Ten days after vaccination the patient developed multiple pustules at the site of vaccination which spread to the patient's neck, chest and arms. The patient also experienced sore throat with minimal exudate on the right tonsil. He reported difficulty swallowing, mild fever, and rhinorrhea. The anterior cervical lymph node was tender to palpation. No additional information was provided.
Age: 37.0
Sex: M
Vaccine: SMALL
Symptoms: Rhinorrhoea
Clinical narrative: This case was received on 14 September 2009 via a QScan search on the VAERS database, under reference number 351130. A 37 year old male patient received a percutaneous injection of smallpox (vaccinia) vaccine (ACAM2000, lot number VV04-003A) on 01 July 2009. Ten days after vaccination the patient developed multiple pustules at the site of vaccination which spread to the patient's neck, chest and arms. The patient also experienced sore throat with minimal exudate on the right tonsil. He reported difficulty swallowing, mild fever, and rhinorrhea. The anterior cervical lymph node was tender to palpation. No additional information was provided.
Age: 28.0
Sex: M
Vaccine: SMALL
Symptoms: Blister, Cellulitis, Chills
Clinical narrative: This case was received on 14 September 2009 via a QScan search on the VAERS database under reference number 351418. A 28 year old male patient received a percutaneous injection of ACAM2000, lot number VV04003A on 25 June 2009. Eight days after vaccination, the patient developed cellulitis (6.5 cm surrounding a blister). The patient also reported chills for 3 days. The patient was treated with Doxycycline (100 mg, BID). The patient recovered. List of documents held by sender: none.
Age: 25.0
Sex: M
Vaccine: SMALL
Symptoms: Cellulitis
Clinical narrative: This case was received on 14 September 2009 via a QScan search on the VAERS database. A 25 year old male patient received a percutaneous injection of VACCINIA (ACAM2000, lot number not reported) on 17 June 2009. Four days after vaccination, the patient developed cellulitis secondary to smallpox vaccination. The patient recovered. Although the manufacturer was reported as unknown in this case, ACAM2000 was the only licensed smallpox vaccine at the time of the patient's vaccination. List of documents held by sender: none.
Age: 21.0
Sex: F
Vaccine: ANTH, SMALL
Symptoms: Generalised vaccinia
Clinical narrative: This case was received on 14 September 2009 via a QScan search on the VAERS database. A 21 year old female patient received the following vaccines on 08 July 2009: a percutaneous injection of VACCINIA (ACAM2000, lot number unknown); and an intramuscular injections of BIOTHRAX, Emergent Biosolutions, lot number unknown. Sites of administration were not reported. One day after vaccination, the patient developed generalized vaccinia. No additional information was provided. List of documents held by sender: none.
Age: 23.0
Sex: M
Vaccine: SMALL, TYP
Symptoms: Blood creatine phosphokinase MB normal, Blood creatine phosphokinase normal, Chest pain, Decreased appetite, Dyspepsia
Clinical narrative: A 23 year old male patient received the following vaccines on 24 June 2009: a percutaneous injection of smallpox (vaccinal vaccine, live (ACAM200, lot number VV04003A); and an intramuscular injection of typhoid vaccine (manufacturer unknown and lot number not reported). The sites of administration were not reported. Nine days after vaccination, the patient developed chest pain that worsened to 8 out 10 on a pain scale. The patient was seen at the Emergency Room. The assessment was heartburn from taking over the counter NSAIDs for treatment of a robust take at the smallpox vaccination site. The patient also complained of decreases appetite, fatigue and shortness of breath. An electrocardiogram performed in the Emergency Room was normal. The following test results were provided form 07 July 2009: Creatine Kinase, 88 (22-269); Troponin T Cardiac, 0.028 (0.00-0.029); Creatine Kinase MB, 2.760 (0-6.73); and ESR 15 min, 25 (H) (0-15). An electrocardiogram was reported as abnormal. The patient recovered.
Age: 23.0
Sex: M
Vaccine: SMALL, TYP
Symptoms: Dyspnoea, Electrocardiogram normal, Fatigue, Red blood cell sedimentation rate increased, Troponin T
Clinical narrative: A 23 year old male patient received the following vaccines on 24 June 2009: a percutaneous injection of smallpox (vaccinal vaccine, live (ACAM200, lot number VV04003A); and an intramuscular injection of typhoid vaccine (manufacturer unknown and lot number not reported). The sites of administration were not reported. Nine days after vaccination, the patient developed chest pain that worsened to 8 out 10 on a pain scale. The patient was seen at the Emergency Room. The assessment was heartburn from taking over the counter NSAIDs for treatment of a robust take at the smallpox vaccination site. The patient also complained of decreases appetite, fatigue and shortness of breath. An electrocardiogram performed in the Emergency Room was normal. The following test results were provided form 07 July 2009: Creatine Kinase, 88 (22-269); Troponin T Cardiac, 0.028 (0.00-0.029); Creatine Kinase MB, 2.760 (0-6.73); and ESR 15 min, 25 (H) (0-15). An electrocardiogram was reported as abnormal. The patient recovered.
Age: 21.0
Sex: M
Vaccine: SMALL, TYP
Symptoms: Blood creatine phosphokinase MB normal, Chest X-ray normal, Chest pain, Dyspnoea, Troponin T
Clinical narrative: This case was received on 14 September 2009 via a QScan search on the VAERS database, under reference number 351487. A 21 year old male patient received the following vaccines on 17 June 2009: a percutaneous injection of smallpox (vaccinia) vaccine, live (ACAM2000, lot number VV04); and an intramuscular injection of typhoid vaccine (manufacturer and lot number unknown). Sites of administration were not reported. Three days after vaccination the patient developed chest pain that lasted approximately one day and resolved without treatment. Approximately 10 days later, the patient complained of shortness of breath, occurring when laying down at night. The following lab tests were reported: Creatine Kinase MB, 2.050 ng/mL; Troponin T Cardiac, <0.010 ng/mL; Creatine Kinase, 73 U/L; and a negative chest x-ray on 26 June 2009. The patient recovered. Note: There may be a discrepancy between the event date field and the onset date information in the free text narrative field in the data reported. Latency has been calculated using the event date.
Age: 27.0
Sex: M
Vaccine: SMALL, SMALL
Symptoms: Alanine aminotransferase increased, Aspartate aminotransferase increased, Blood bilirubin, Blood creatine phosphokinase, Chest X-ray normal
Clinical narrative: This case was received on 14 September 2009 via a Q Scan search on the VAERS database, under reference number 351549. A 27 year-old male patient received the following vaccination on 26 June 2009: smallpox vaccinia vaccine, live (ACAM2000, lot number not reported). Although the manufacturer was reported as unknown in this case, ACAM2000 was the only licensed smallpox vaccine at the time of the patient's vaccination. The patient presented ten days post vaccination with >3 centimeter smallpox lesion, mild to moderate erythema, shortness of breath on exertion, fatigue, malaise, intermittent chest pressure, and generalized aches and pain. The patient's laboratory results as reported were: oxygen saturation: 98%; Complete blood cell count: within normal range; troponin: negatve; myoglobin: positive; creatinine phosphokinase: not done; creatinine phosphokinase-MB: negative; aspartate aminotransferase (AST): 139; alanine aminotransferase (ALT): 39; bilirubin: normal; gamma-glutamyltransferase: normal; chest x ray: normal. The patient's outcome was not reported. No other information was provided. There may be a discrepancy between the event date field and the onset date information in the free text narrative field in the dta reported. Latency has been calculated using the event date. List of documents held by sender: None.
Age: 27.0
Sex: M
Vaccine: SMALL, SMALL
Symptoms: Chest discomfort, Dyspnoea, Erythema, Fatigue, Full blood count
Clinical narrative: This case was received on 14 September 2009 via a Q Scan search on the VAERS database, under reference number 351549. A 27 year-old male patient received the following vaccination on 26 June 2009: smallpox vaccinia vaccine, live (ACAM2000, lot number not reported). Although the manufacturer was reported as unknown in this case, ACAM2000 was the only licensed smallpox vaccine at the time of the patient's vaccination. The patient presented ten days post vaccination with >3 centimeter smallpox lesion, mild to moderate erythema, shortness of breath on exertion, fatigue, malaise, intermittent chest pressure, and generalized aches and pain. The patient's laboratory results as reported were: oxygen saturation: 98%; Complete blood cell count: within normal range; troponin: negatve; myoglobin: positive; creatinine phosphokinase: not done; creatinine phosphokinase-MB: negative; aspartate aminotransferase (AST): 139; alanine aminotransferase (ALT): 39; bilirubin: normal; gamma-glutamyltransferase: normal; chest x ray: normal. The patient's outcome was not reported. No other information was provided. There may be a discrepancy between the event date field and the onset date information in the free text narrative field in the dta reported. Latency has been calculated using the event date. List of documents held by sender: None.
Age: 27.0
Sex: M
Vaccine: SMALL, SMALL
Symptoms: Gamma-glutamyltransferase, Malaise, Myoglobin blood, Pain, Troponin
Clinical narrative: This case was received on 14 September 2009 via a Q Scan search on the VAERS database, under reference number 351549. A 27 year-old male patient received the following vaccination on 26 June 2009: smallpox vaccinia vaccine, live (ACAM2000, lot number not reported). Although the manufacturer was reported as unknown in this case, ACAM2000 was the only licensed smallpox vaccine at the time of the patient's vaccination. The patient presented ten days post vaccination with >3 centimeter smallpox lesion, mild to moderate erythema, shortness of breath on exertion, fatigue, malaise, intermittent chest pressure, and generalized aches and pain. The patient's laboratory results as reported were: oxygen saturation: 98%; Complete blood cell count: within normal range; troponin: negatve; myoglobin: positive; creatinine phosphokinase: not done; creatinine phosphokinase-MB: negative; aspartate aminotransferase (AST): 139; alanine aminotransferase (ALT): 39; bilirubin: normal; gamma-glutamyltransferase: normal; chest x ray: normal. The patient's outcome was not reported. No other information was provided. There may be a discrepancy between the event date field and the onset date information in the free text narrative field in the dta reported. Latency has been calculated using the event date. List of documents held by sender: None.
Age: 27.0
Sex: M
Vaccine: SMALL, SMALL
Symptoms: Chest X-ray normal, Chest pain, Dyspnoea, Echocardiogram, Electrocardiogram abnormal
Clinical narrative: This case was received on 14 September 2009 via a Q Scan search on the VAERS database, under reference number 351549. A 27 year-old male patient received the following vaccination on 26 June 2009: smallpox vaccinia vaccine, live (ACAM2000, lot number not reported). Although the manufacturer was reported as unknown in this case, ACAM2000 was the only licensed smallpox vaccine at the time of the patient's vaccination. The patient presented ten days post vaccination with >3 centimeter smallpox lesion, mild to moderate erythema, shortness of breath on exertion, fatigue, malaise, intermittent chest pressure, and generalized aches and pain. The patient's laboratory results as reported were: oxygen saturation: 98%; Complete blood cell count: within normal range; troponin: negatve; myoglobin: positive; creatinine phosphokinase: not done; creatinine phosphokinase-MB: negative; aspartate aminotransferase (AST): 139; alanine aminotransferase (ALT): 39; bilirubin: normal; gamma-glutamyltransferase: normal; chest x ray: normal. The patient's outcome was not reported. No other information was provided. There may be a discrepancy between the event date field and the onset date information in the free text narrative field in the dta reported. Latency has been calculated using the event date. List of documents held by sender: None.
Age: 27.0
Sex: M
Vaccine: SMALL, SMALL
Symptoms: Fatigue, Headache, Musculoskeletal stiffness, Pain in extremity, Palpitations
Clinical narrative: This case was received on 14 September 2009 via a Q Scan search on the VAERS database, under reference number 351549. A 27 year-old male patient received the following vaccination on 26 June 2009: smallpox vaccinia vaccine, live (ACAM2000, lot number not reported). Although the manufacturer was reported as unknown in this case, ACAM2000 was the only licensed smallpox vaccine at the time of the patient's vaccination. The patient presented ten days post vaccination with >3 centimeter smallpox lesion, mild to moderate erythema, shortness of breath on exertion, fatigue, malaise, intermittent chest pressure, and generalized aches and pain. The patient's laboratory results as reported were: oxygen saturation: 98%; Complete blood cell count: within normal range; troponin: negatve; myoglobin: positive; creatinine phosphokinase: not done; creatinine phosphokinase-MB: negative; aspartate aminotransferase (AST): 139; alanine aminotransferase (ALT): 39; bilirubin: normal; gamma-glutamyltransferase: normal; chest x ray: normal. The patient's outcome was not reported. No other information was provided. There may be a discrepancy between the event date field and the onset date information in the free text narrative field in the dta reported. Latency has been calculated using the event date. List of documents held by sender: None.